Status:
NOT_YET_RECRUITING
Surgical vs Percutaneous LAAO
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Atrial fibrillation is the most common cardiac arrythmia globally. Its prevalence ranges between 2-4% worldwide. It is associated with significant morbidity and mortality. One of the main concerns of ...
Eligibility Criteria
Inclusion
- Atrial fibrillation diagnosis
- Underwent LAA clip (Atriclip) or left atrial appendage occlusion with CHADVASC \>=2
Exclusion
- Subject not required anticoagulation due to low CHADVASC
- Mechanical valve replacement
- Tissue mitral valve replacement or tissue aortic valve replacement with underlying chronic rheumatic heart disease
Key Trial Info
Start Date :
October 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT05420701
Start Date
October 1 2022
End Date
December 31 2026
Last Update
September 21 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.